Franchimont D, Galon J, Gadina M, Visconti R, Zhou Y, Aringer M, Frucht D M, Chrousos G P, O'Shea J J
Lymphocyte Cell Biology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
J Immunol. 2000 Feb 15;164(4):1768-74. doi: 10.4049/jimmunol.164.4.1768.
Glucocorticoids are widely used in the therapy of inflammatory, autoimmune, and allergic diseases. As the end-effectors of the hypothalamic-pituitary-adrenal axis, endogenous glucocorticoids also play an important role in suppressing innate and cellular immune responses. Previous studies have indicated that glucocorticoids inhibit Th1 and enhance Th2 cytokine secretion. IL-12 promotes Th1 cell-mediated immunity, while IL-4 stimulates Th2 humoral-mediated immunity. Here, we examined the regulatory effect of glucocorticoids on key elements of IL-12 and IL-4 signaling. We first investigated the effect of dexamethasone on IL-12-inducible genes and showed that dexamethasone inhibited IL-12-induced IFN-gamma secretion and IFN regulatory factor-1 expression in both NK and T cells. This occurred even though the level of expression of IL-12 receptors and IL-12-induced Janus kinase phosphorylation remained unaltered. However, dexamethasone markedly inhibited IL-12-induced phosphorylation of Stat4 without altering its expression. This was specific, as IL-4-induced Stat6 phosphorylation was not affected, and mediated by the glucocorticoid receptor, as it was antagonized by the glucocorticoid receptor antagonist RU486. Moreover, transfection experiments showed that dexamethasone reduced responsiveness to IL-12 through the inhibition of Stat4-dependent IFN regulatory factor-1 promoter activity. We conclude that blocking IL-12-induced Stat4 phosphorylation, without altering IL-4-induced Stat6 phosphorylation, appears to be a new suppressive action of glucocorticoids on the Th1 cellular immune response and may help explain the glucocorticoid-induced shift toward the Th2 humoral immune response.
糖皮质激素广泛应用于炎症性、自身免疫性和过敏性疾病的治疗。作为下丘脑 - 垂体 - 肾上腺轴的终效应器,内源性糖皮质激素在抑制先天性和细胞免疫反应中也发挥着重要作用。先前的研究表明,糖皮质激素抑制Th1细胞并增强Th2细胞因子的分泌。IL - 12促进Th1细胞介导的免疫反应,而IL - 4刺激Th2体液介导的免疫反应。在此,我们研究了糖皮质激素对IL - 12和IL - 4信号传导关键元件的调节作用。我们首先研究了地塞米松对IL - 12诱导基因的影响,结果表明地塞米松在NK细胞和T细胞中均抑制IL - 12诱导的IFN - γ分泌以及IFN调节因子 - 1的表达。即便IL - 12受体的表达水平以及IL - 12诱导的Janus激酶磷酸化保持不变,这种情况仍会发生。然而,地塞米松显著抑制IL - 12诱导的Stat4磷酸化,但其表达未发生改变。这具有特异性,因为IL - 4诱导的Stat6磷酸化不受影响,并且是由糖皮质激素受体介导的,因为它可被糖皮质激素受体拮抗剂RU486拮抗。此外,转染实验表明,地塞米松通过抑制Stat4依赖的IFN调节因子 - 1启动子活性降低了对IL - 12的反应性。我们得出结论,在不改变IL - 4诱导的Stat6磷酸化的情况下,阻断IL - 12诱导的Stat4磷酸化似乎是糖皮质激素对Th1细胞免疫反应的一种新的抑制作用,这可能有助于解释糖皮质激素诱导的向Th2体液免疫反应的转变。